Porsolt SAS, a long established preclinical screening, efficacy, and safety 
CRO, has completed a significant expansion of its research facility, adding a 
further 5,500 sq.ft. of experimental space.
 
The expansion integrates Porsolt's new areas of research, cutting edge 
technologies, increased in vitro capabilities, and growing portfolio of 
preclinical models. This enhances Porsolt's ability to employ predictive tools, 
including cell-based models, to meet the requirements of the pharmaceutical and 
biotech industries and optimize drug discovery pipelines.

The additional research space comprises in vitro laboratories including cell 
culture, flow cytometry, histology, imaging, and analysis, that have been 
incorporated from Fluofarma. Porsolt has also expanded its chemistry, 
biochemistry, biomarker, ex-vivo capabilities, and housing capacity for in vivo 
studies. 

"This is reflective of the consistent growth of Porsolt SAS over recent years, 
incorporating new areas of research and specialized expertise," commented Dr. 
Guillaume Froget, President and CEO of Porsolt SAS. "This enables us to 
continue to meet the needs of our expanding global client base, covering more 
stages in the drug discovery process." 

Porsolt has an international reputation for expertise in physio-pathological 
models, customized procedures, and tailored solutions for discovering 
treatments in multiple disease areas, including psychiatric and neurological 
disorders, oncology, acute and chronic pain, inflammation, cardiac and vascular 
diseases, metabolic and eating disorders, dermatology, and medical devices, 
using in vitro cell lines and in vivo disease models in multiple species. 
Porsolt also provides GLP safety evaluation of drug candidates from screening 
to regulatory studies before first-in-man administration, including predictive 
toxicology, full assessment of cardiac risk, and abuse and dependence 
liability. 

About Porsolt 

Porsolt SAS, located in Le Genest-Saint-Isle, France, works with pharmaceutical 
and biotechnology companies, academic institutes, and not-for-profit 
organizations, offering specialized preclinical testing services across many 
disease areas, physiological systems and processes. Porsolt provides services 
in vitro and in vivo discovery, screening, efficacy and safety pharmacology 
using standardized and innovative techniques in full compliance with GLP (ICH 
S7). For additional information about the organization, please visit 
www.porsolt.com or email us at contact@porsolt.com.

Logo - https://mma.prnewswire.com/media/969121/Portsolt_Logo.jpg 

Contact: 
Dr David Pushett 
contact@porsolt.com

Source: Porsolt